ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept …
